welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
completed
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
status: completed
purpose:This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
intervention: CRD007
mechanism of action: Non-steroidal agent to decrease inflammation
results: https://clinicaltrials.gov/ct2/show/results/NCT01540604
last updated: November 22, 2018
study details
study contacts
rareRelated
-
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
-
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD)The GalaxyDMD study is a global Phase 3,...
-
First Patient Enrolled in Mallinckrodt’s Phase 2 Duchenne Muscular Dystrophy TrialMallinckrodt plc, a leading global spec...
-
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
